TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a Body Mass Index (BMI) \>= 30kg/m\^2~Exclusion Criteria:~* Have ever participated in this study previously, or any other study using exenatide (AC2993/LY2148568) or GLP-1 analogs~* Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of study start (this criterion includes drugs that have not received regulatory approval for any indication at the time of study entry)~* Diagnosis of diabetes mellitus (other than gestational diabetes), or previous use of anti-diabetic medications for \> 3 months~* Have had a change in prescribed lipid-lowering or blood pressure agents within 4 weeks of screening~* Used drugs for weight loss (e.g., Xenical \[orlistat\], Meridia \[sibutramine\], Acutrim \[phenylpropanolamine\], Accomplia \[rimonabant\], Alli \[low-dose orlistat\], or other similar over-the-counter weight loss remedies or medications) within 3 months of screening~* Are actively participating in, or have participated in a formal weight loss program within the last 3 months~* Have a history of chronic use of drugs that directly affect gastrointestinal motility, including, but not limited to Reglan (metoclopramide) and chronic macrolide antibiotics~* Have been treated with any anti-diabetic medications within 3 months of screening~* Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy or have received such therapy within the 4 weeks immediately prior to study start~* Have had bariatric surgery~* Have had an organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): None
- Group B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age (either gender and any race);~* Reported history of dry eye for at least 6 months prior to Visit 1;~* Reported history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1~Exclusion Criteria:~* Clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;~* Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;~* Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during the trial;~* Eye drop use within 2 hours of Visit 1;~* Previous laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;~* Cyclosporine 0.05% or 0.09% or lifitegrast 5.0% ophthalmic solution use within 90 days of Visit 1;~* Be receiving systemic corticosteroid therapy (not including inhaled corticosteroids) within 14 days of Visit 1 or anticipate such therapy throughout the study period;~* Planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;~* Temporary punctal plugs during the study that have not been stable within 30 days of Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days (Type: EXPERIMENTAL): None
- Vehicle Ophthalmic Solution administered 7 times over two consecutive days (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ME/CFS according to Canadian criteria (2003)~* Duration of ME/CFS at least 2 years~* Mild/Moderate, Moderate, Moderate/Severe and Severe ME/CFS may be included~* Age 18-65 years~* Signed informed consent~Exclusion Criteria:~* Patients with fatigue who do not comply by the diagnostic Canadian criteria (2003) for ME/CFS~* Duration of ME/CFS less than 2 years~* Mild ME/CFS~* Very severe ME/CFS (bedridden requiring help for all tasks)~* Patients where the workup uncovers other pathology as possible cause of symptoms~* Pregnancy or breast feeding~* Previous malignant disease (except basal cell carcinoma of skin and cervical carcinoma in situ/dysplasia)~* Previous long-term systemic treatment with immunosuppressive agents (e.g. azathioprine, ciclosporin, mycophenolate mofetil). Except steroid treatment for e.g. obstructive lung disease or autoimmune diseases such as e.g. ulcerative colitis~* Serious endogenous depression~* Lack of ability to complete the study including follow-up~* Reduced renal function (creatinine \> 1.5 x UNL)~* Reduced liver function (bilirubin or transaminases \> 1.5 x UNL)~* Known hypersensitivity to cyclophosphamide or metabolites~* Reduced bone marrow function~* Ongoing cystitis or urinary tract obstruction~* Known HIV positivity, previous hepatitis B or hepatitis C, or reason to suspect other ongoing and clinically relevant infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide (Type: EXPERIMENTAL): Cyclophosphamide, intravenous infusions four weeks apart. Six infusions in total. First infusion: 600 mg/m2. Infusions 2 to 6: 700 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Masked Faces in Parkinson Disease: Mechanism and Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of idiopathic Parkinson disease~* Hoeh-Yahr Stage 1-3 when off medication~* Stable and optimal medical regimen for at least 3 months~* No previous surgical interventions for Parkinson's disease (i.e., deep brain stimulation, pallidotomy, stem cell implantation)~* Participants will include men and women between the ages of 45 and 80 years~Exclusion Criteria:~* Evidence of dementia based on neurocognitive testing~* Current or past history of major psychiatric disturbance (e.g., schizophrenia, bipolar disorder, substance abuse). Participants who are taking anti-depressants will not be excluded as long as they are not currently depressed (Beck Depression, SCID)~* Other neurologic disturbance (e.g., tumor, stroke, traumatic brain injury, epilepsy) or severe chronic medical illness (e.g., HIV, metastatic cancer)~* Presence of oro-facial dyskinesias~* Previous surgeries to the larynx that result in poor vocal fold closure and/or positive history of head and neck cancer~* History of smoking in the past 5 years~* Untreated hypertension~* Failing a baseline test of pulmonary function during baseline respiratory evaluation~* Known respiratory complications such as chronic obstructive pulmonary disease (POCD), asthma~* Previous surgical interventions for Parkinson's disease (i.e., deep brain stimulation, pallidotomy, stem cell implantation)

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- High Intensity Muscle Strength Training (Type: ACTIVE_COMPARATOR): This arm involved high intensity muscle strength training at 75% maximum inspiratory pressure (MIP). Training took place for 4 weeks, 5 days a week. Each daily session involved 5 sets of breathing exercises that required participants to take deep breaths (i.e., inspire) using use a breathing device. Settings on the breathing device were determined by obtaining the individual's maximal inspiratory pressure (MIP)using a specialized breathing gauge. The MIP was determined at the beginning of each week and the training device was adjusted and set at 75% MIP. Exercises took place in home setting, with weekly visit by staff. Participants kept daily exercise log.
- Sham MST (Type: SHAM_COMPARATOR): This arm (low intensity MST) was identical to the real intervention in all ways except that the training device was set at 5% maximum inspiratory pressure (MIP). Thus less muscle and breathing effort was required during this sham treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* 12 years of age or older (at least 18 years in Croatia, France and United Kingdom (UK))~* Clinical diagnosis of congenital haemophilia A or B with a current positive inhibitor titre and a known peak inhibitor of above 5 Bethesda units (BU) (present or in the past) to human FVIII or IX and known antihuman FVIII or IX anamnestic response~* Minimum of 2 joint bleeds (haemarthroses of ankles, knees, or elbows) requiring haemostatic drug treatment within the previous 6 months, or at least 4 joint bleeds (hemarthroses of ankles, knees, or elbows) requiring haemostatic drug treatment within the previous 12 months at trial entry~Exclusion Criteria:~* Known allergy to rFVIIa, and/or suspected allergy to trial product~* Platelet count lower than 50,000 mm\^3 based on medical records at trial entry (visit 1)~* Any clinical signs or history of thromboembolic events~* Advanced atherosclerotic disease~* Severe liver disease based on medical records within the past 12 months at trial entry (Visit 1), as defined by alanine aminotransferase (ALAT) above 3 times the upper limit of normal reference range~* Known active pseudo tumours (documented bleeding requiring treatment within the last 3 months~* Subject had any (major) surgical procedure in the 30 days prior to screening into the trial. a. Catheter, ports and dental extractions do not count as surgeries and will not exclude the subject

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vatreptacog alfa 5 mcg/kg (Type: EXPERIMENTAL): None
- vatreptacog alfa 10 mcg/kg (Type: EXPERIMENTAL): None
- vatreptacog alfa 20 mcg/kg (Type: EXPERIMENTAL): None
- vatreptacog alfa 40 mcg/kg (Type: EXPERIMENTAL): None
- vatreptacog alfa 80 mcg/kg (Type: EXPERIMENTAL): None
- rFVIIa 90 mcg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women aged ≥18 years~2. Pregnancy at GA 14+0 - 19+0~3. Ferritin \<30 μg/L after 4 weeks of standard treatment in a clinical setting~4. Willingness to participate and attend all planned follow-up visits, and signing the in-formed consent form~Exclusion Criteria:~1. History of anaemia caused by e.g. thalassemia, hypersplenism or haemolytic anaemia (known haematologic disorder other than iron deficiency)~2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)~3. Drug hypersensitivity (i.e. previous hypersensitivity to IV iron)~4. Known hypersensitivity to any excipients in the investigational drug products~5. History of active asthma within the last 5 years~6. History of multiple allergies~7. Known decompensated liver cirrhosis or active hepatitis~8. Active acute or chronic infections (assessed by clinical judgement)~9. Rheumatoid arthritis with symptoms or signs of active inflammation~10. Treated with IV iron products or blood transfusion within 4 weeks prior to inclusion~11. Treated with erythropoietin (EPO) within 4 weeks prior to inclusion~12. Participation in any other interventional trial where the trial drug has not passed 5 half-lives prior to inclusion~13. Any other medical condition that, in the opinion of the Investigator, may cause the subject to be unsuitable for the completion of the trial or place the subject at potential risk from being in the trial~14. Meeting RBC-transfusion criteria (Hb ≤6.9 g/dL= 4.3 mmol/L with intolerable symptoms of anaemia like severe palpitations, severe dizziness, shortness of breath at rest or syncope or an Hb ≤6.4 g/dL (4.0 mmol/L) without intolerable symptoms of anaemia)~15. Multiple pregnancies~16. Inability to read and understand the Danish language

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV administration (Type: EXPERIMENTAL): Iron isomaltoside (Monofer) Administered iv
- Oral administration (Type: ACTIVE_COMPARATOR): Ferrous fumarate with ascorbic acid Administered oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute myeloid leukemia by immunophenotyping, morphology, and cytochemical staining; myelodysplasia; or biphenotypic leukemia.~* Age less than or equal to 21 years at time of study entry.~* No prior therapy for this malignancy (patients with secondary AML following treatment of primary malignancy are eligible) except for one dose of intrathecal therapy.~* Negative pregnancy test~* Patient does not have Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia (JMML)~Exclusion Criteria:~* Positive pregnancy test~* Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia (JMML)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- HDAC (High-Dose Cytarabine) (Type: EXPERIMENTAL): Since limited characters are allowed in this passage, please see detailed Description for HDAC.
- LDAC (Low-Dose Cytarabine) (Type: EXPERIMENTAL): Since limited characters are allowed in this passage, please see detailed Description for LDAC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Signatures and Biomarkers in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years~* Diagnosis of schizophrenia~* Actively psychotic~* No more than a single dose of antipsychotic in the preceding 2 weeks~Exclusion Criteria:~* Mental retardation, epilepsy or history of head trauma~* Substance use disorder that explains the majority of the psychopathology~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Aripiprazole for 4 weeks (Type: ACTIVE_COMPARATOR): Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
- Risperidone for 4 weeks (Type: ACTIVE_COMPARATOR): Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.
- Healthy volunteers (Type: OTHER): Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 to 80 years of age with Primary hypercholesterolemia or mixed dyslipidemia~* Patients will be eligible for the study if their LDL-C values are within protocol specified range and meet other entry criteria~Exclusion Criteria:~* Patient whose LDL-C values are not within protocol specified range

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
- 2 (Type: ACTIVE_COMPARATOR): Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic confirmation of malignancy at Memorial Sloan-Kettering~* Patients must have previously untreated stage I or II NSCLC (T11-2N0M0, T1-2N1M0, T3N0M0) and 1 of the following features: never smoker or \< 15 pack year smoking history and/or bronchioloalveolar cancer (either pure BAC, BAC with focal invasion or adenocarcinoma with BAC features)~* Patients must have been determined to be operable and resectable by the treating thoracic surgeon.~* Age \>18 years.~* Measurable indicator lesions~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Pregnant or lactating women or women of childbearing potential not using effective contraception. Men participating in the trial must also use effective contraception when sexually active.~* Patients may not be receiving any other investigational agents.~* Any history of or evidence of interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Amputation Surgical Site Infection Trial (ASSIT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults ≥18 yrs undergoing lower limb amputations who are able to consent to the trial.~2. Able to understand the Patient Information Sheet and capable and willing to give informed consent and follow the protocol requirements (including attending all follow-up visits)~Exclusion Criteria:~1. Allergies to chlorhexidine/ alcohol/ iodophors~2. Inability to give informed consent~3. Patients who are admitted to hospital with severe sepsis secondary to gas gangrene requiring multiple operations and admission to Intensive Care Unit.~4. Aged under 18 years at the time of recruitment~5. Use of investigational drug/device therapy within preceding 4 weeks that may interfere with this study.~6. Toe amputations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 24 hour antibiotic course (Type: ACTIVE_COMPARATOR): 24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)
- 5 day antibiotic Course (Type: ACTIVE_COMPARATOR): 24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)
- Iodine (Type: ACTIVE_COMPARATOR): Skin Preparation used pre-operatively: Alcoholic Povidone
- Chlorhexidine (Type: ACTIVE_COMPARATOR): Skin preparation to be used preoperatively: Alcoholic chlorhexidine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete